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Abstract
Background: The motivations of clinicians to participate in clinical trials have been little studied.
This project explored the potential role of payment for participation in publicly funded clinical trials
in the UK. The aims were to review relevant guidelines and to collate and analyse views of clinical
trialists on the role of payments and other factors that motivated clinicians to join clinical trials.
Methods: Review of guidelines governing payments to clinicians for recruitment to trials. Semi-
structured interviews with a range of NHS clinical trial leaders, analysed using qualititative methods.
Results: While UK guidelines had little to say specifically on payments linked to recruitment, all
payments have become highly regulated and increasingly transparent. Interview participants
believed that expenses arising from research should be covered. Payments in excess of expenses
were seen as likely to increase participation but with the risk of reducing quality. Motivations such
as interest in the topic, the scope for patients to benefit and intellectual curiosity were considered
more important. Barriers to involvement included bureaucracy and lack of time.
Discussion: Limited scope exists for paying clinicians over-and-above the cost of their time to be
involved in research. Most trialists favour full payment of all expenses related to research.
Conclusion: Payment of clinicians beyond expenses is perceived to be a less important motivating
factor than researching important, salient questions, and facilitating research by reducing
bureaucracy and delay.
Background
Most clinical trials in the UK fail to meet their recruitment
targets [1]. An analysis of multicentre trials funded by
HTA and MRC showed that 45% failed to reach 80% of
target.[2] Only 10% of eligible patients were recruited in
a review of one trial [3]. Less than half of participating cli-
nicians succeeded in recruiting any patients in two other
trials[4,5]. Commercial trials report similar problems
with 30% of sites failing to recruit a single patients and
70% failing to meet agreed recruitment targets [6]. Studies
that recruit too few patients might not only miss clinically
important effects, but raise ethical questions about expos-
ing volunteers to new treatments in inconclusive research.
Slow recruitment can increase the cost of trials and delay
the production of important evidence. Identified barriers
included: time constraints, lack of staff and training, wor-
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ries about the doctor-patient relationship, concern for
patients, loss of professional autonomy, consent proce-
dures and the lack of reward and recognition [1,7]. A sys-
tematic review [8] of incentives for participation indicated
the importance of personal links between lead researcher
and collaborating clinicians. Another systematic review
[9] of the role of payments for participation located only
three studies, none from the UK, all indicating that pay-
ment was of minor importance. All of these reviews rec-
ommended further research.
This study had three objectives:
• To outline current UK practice regarding the payment of
financial incentives to healthcare professionals for recruit-
ment of patients to trials.
￿ To explore the attitudes, beliefs and behaviour of health-
care researchers in relation to financial incentives for
recruitment to trials.
￿ To indicate how financial incentives are viewed in rela-
tion to other barriers and facilitators to healthcare profes-
sionals recruiting patients to clinical trials.
Financial incentives include paying individual recruiters
in cash, such as per recruit enrolled, or reimbursing to the
practice or trust to cover additional costs associated with
participation in a trial [10]. Gifts can be seen as equivalent
to cash payments.
A fuller account of this research, funded by the NHS HTA
Programme has been published [11] and is available
online.
Methods
To meet the first objective searches of bibliographic data-
bases, and direct inquiries to key UK agencies and searches
of their websites were undertaken in June 2006 to identify
UK guidelines related to payment of clinicians in research.
We also undertook web searching using Google. The data-
base search was carried out in parallel with a literature
review of studies examining the effectiveness of incentives
and we looked for guidelines during the inclusion/exclu-
sion process of the effectiveness review [11]. The UK agen-
cies included the major research funders (such as the
Medical Research Council and Wellcome Trust), profes-
sional organisations (such as the Association of the British
Pharmaceutical Industry and the British Medical Associa-
tion), and other research stakeholders such as the Central
Office for Research Ethics Committees.
To meet the other objectives, semi-structured interviews
were undertaken with researchers who had led clinical tri-
als. A draft interview schedule was refined after eight pilot
interviews [11]. In the schedule questions were structured
around two main themes: the motivations for taking part
in clinical trials (their personal motivations and their
views of other's motivations); and their experience of and
attitudes towards the use of incentives for recruitment.
Approval for the study was granted by the Southampton
and South West Hampshire Research Ethics Committee.
Researchers were selected to reflect diversity in five dimen-
sions:
￿ Geographical location
￿ Primary and secondary care settings
￿ Clinicians and non-clinicians
￿ A range of specialties
￿ Currently active and inactive researchers
Lead investigators in ongoing trials in April 2006 funded
by the NHS HTA Programme were identified from the
public database Current Clinical Trials [11]. Of these 38
(27 doctors, 2 nurses and 9 non-clinical) were invited to
participate. Six other clinicians with research experience
who were no longer active in research were interviewed,
having been identified by snowball sampling. All the
active researchers approached agreed to be interviewed.
Two thirds of inactive researchers identified through
snowball sampling refused (six agreed, 12 refused).
All 44 interviews took place at the respondents' place of
work between September 2005 and April 2006. All were
audio- recorded and fieldnotes were made. Two investiga-
tors (CK and SH) individually undertook line-by-line
open coding of all transcripts to identify empirically
grounded [13]descriptive labels for phenomena related to
the research aims. After comparison and discussion an
agreed system of coding was devised and applied,
approved by the wider research team who each read a
sample of transcripts. NVIVO was used to assist data man-
agement and analysis [14].
Results
Review of guidelines
The review of guidelines on payment for involvement in
clinical trials indicated that NHS organisations must
charge the full cost for commercial trials [15], using the
model Clinical Trial Agreement [16] unless good reasons
exist to the contrary. Payment should be to the relevant
NHS trust rather than to individual clinicians [14] and
could be in the form of an amount per patient recruited
[16]. Ethics committee approval, which is mandatory
[17], requires submission of full information on all pay-Trials 2009, 10:15 http://www.trialsjournal.com/content/10/1/15
Page 3 of 6
(page number not for citation purposes)
ments to researchers and patients. General Medical Coun-
cil guidelines [18] require doctors engaged in research to
disclose to patients entering trials how the research is
funded and of any benefits to them or their departments.
Two points were striking: first that the guidelines said little
about payments to individuals and secondly, what was
said tended to focus on commercially funded trials. The
Association of British Pharmaceutical Industries [19],
Medical Research Council [20], British Medical Associa-
tion [21] and Department of Health guidelines [22,23]
did not mention payments to individual clinicians. The
General Medical Council guidelines [18] were the most
emphatic in requiring transparency on all payments but
provided no indication of what levels of payments might
be appropriate.
Interview study
The semi-structured interviews explored the issue of pay-
ment for participation in trials and the relative impor-
tance of other motivating factors. The participants
included thirteen primary care clinicians, fourteen sec-
ondary care clinicians, two other healthcare professionals,
nine non-clinical researchers, and six non-research-active
clinicians. The following themes were identified:
Expenses versus incentives
Regarding payments, the interviews found that partici-
pants drew a strong distinction between expenses and
payment over-and-beyond expenses. The former were
strongly supported while the latter were not. This reim-
bursement was felt to be particularly important in under-
taking research in primary care. As this respondent noted,
"I think the key thing if you're doing a trial in primary care
now, if you don't offer any money then it's not going to happen"
(HR6).
Positive effects of incentives
Payments were seen as both improving recruitment and a
way of acknowledging the work of others, valuing their
time and showing respect. "If people feel respected and their
time valued, they will do a lot more for it" (GP3). Some lead
researchers were already paying collaborators an amount
per patient recruited, based on the estimated cost. This
was seen as proportional, rewarding effort and enabling
quality control. A related topic was the idea of a market
economy in research participant recruitment and the need
(particularly in primary care) to compete with pharma-
ceutical industry funded trials. "The money falling where the
patient is is important to ensure recruitment. There's no doubt
if we had, for example, offered an incentive of a certain number
of pounds to a service we're delivering x number of patients that
would have improved recruitment without a doubt. With the
ability to penalise the people if they don't" (HD2).
Negative effects of incentives
Many thought that while paying clinicians improved
recruitment it could reduce quality. "I mean indeed the
more you get paid the more you're going to... the more the impe-
tus is to act unethically. You know, theoretically if I'm getting
10 grand per patient as opposed to £10, I want to give them the
bloody disease, you know" (HD11). Concerns were raised
about payments creating conflicts of interest. "I think there
is a bit of a conflict of interest over what's going to be best for
the patient what's going to be best for my bank balance"
(GP13). Interviews also revealed worries about possible
reductions in the rigour of research, with the possible
threats of ineligible or coerced participants being
recruited, or even fraud in the form of imaginary patients.
"I think the problems clearly are fraud, of misuse of the system
as there are with any form of benefit and I think fraud is the
main one, either if patients are getting money, fraud on their
part, or fraud from doctors, nurses or abuse of the system"
(GP8). Some interviewees feared that financial payments
in excess of costs could erode altruism and encourage
'unsuitable' researchers who would provide lower quality
research.
Principles for payments
Interviewees suggested principles for payments: good
study design, payments to organisations rather than indi-
viduals, and improved transparency and disclosure.
"There are a number of elements for good practice in that, one
is not over-recruiting from any one centre, another is making
sure that you assess centres properly and making sure that the
people there are trained properly and all those things reduce the
potential for bad practice. But you have a place that's well
organised and you are sort of giving them money that recom-
penses their, that covers their expenses, I think it is unlikely to
be a place that is going to run into ethical issues" (HR5).
"There needs to be a clear process, explicit process as to why it's
happening, where the benefit is being seen. I think there is a sig-
nificant danger in an individual receiving money... And that's
the major one I think" (HD2).
The following probity tests were suggested:
"If you are embarrassed about the amount of money you are
being paid for the job you are doing, then you are being paid too
much. You know, if you are being paid £500 for recruiting this
person into this study, and you're going to be embarrassed about
that – well you are asking too, you shouldn't be doing it"
(GP10).
"I think the ultimate test I've always applied is "(Are you),
would you be comfortable discussing [payments] with a
patient?"(HD8).Trials 2009, 10:15 http://www.trialsjournal.com/content/10/1/15
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Motivating factors for research participation
The most prominent factors that encouraged research par-
ticipation, were: interest in the research question, intellec-
tual curiosity and potential benefit to patients (including
access to treatments or drugs, and closer monitoring). For
example, "I think it's important ... It needs to be quite concise
and it will ring people's bell. Some topics are interesting to cer-
tain people and they are more likely to recruit to those" (HD7).
"Well certainly the evidence suggests that patients who go into
trials get better health care. That's certainly, well maybe not
evidence, but it's certainly the anecdote, I believe there probably
is some evidence there, but I haven't looked at it ...You get, well
that's something, you get more attention. And therefore if you
get more attention one assumes you get better health care over-
all" (HR5). Against this they noted the risk that patients
could be randomised to a non-treatment group.
Less prominent motivating factors included altruism and
career progression. Most believed altruism was a dimin-
ishing factor because of increased reliance on money and
increased regulation of trials. Many thought all clinicians
should be required to take part in research. Recognition
and enhancement of reputation were a further minor
theme but again were not seen as primary motivating fac-
tors. Likewise publication authorship was not seen as a
prominent motivation. Publicly-funded trials were
thought preferable to those funded by the pharmaceutical
industry, with many spontaneous criticisms of the latter.
Barriers to taking part in clinical trials
Lack of time was the main reason given for not taking part
in trials. "...but what happens is you kind of join up and don't
foresee just quite how much time commitment it is and then
you're in, even with the best will in the world, in your surgery
and unless I've got spaces I just don't have the time to do it or
else I will put all my patients back half an hour and you don't
want to do that ... So I didn't recruit any patients and it was a
time issue" (GP13). Trials, many suggested, should be
designed to cause the minimum disruption to clinical
practice. Research time had to compete with targets in the
new consultants' and GP contracts. Bureaucracy was seen
as a major barrier to research involvement. The EU Direc-
tive on Good Clinical Practice, the Data Protection Act,
and NHS research governance were all criticised as unduly
restrictive. "I think it's [research] become much, much more
difficult to do as such because of research governance. I think
that a lot of people in the NHS are completely baffled by
research governance and they're terrified of doing the wrong
thing" (HR1).
Contextual factors
The culture of the NHS was seen as prioritising clinical
work over research but for some clinicians research pro-
vided a welcome alternative. The need for a culture that
valued research within the NHS was widely stated. "So yes
we need an NHS that is completely research conscious, wanting
research to happen but that doesn't mean that everybody needs
to be a researcher" (HR2). Training in research, it was sug-
gested, should start before clinicians got 'bogged down' by
clinical work and private practice. Good communication
within research projects was seen as essential: this meant
keeping collaborators informed, building rapport and cre-
ating good working relationships. "(We've) always had very
charismatic, well organised people doing the day-to-day trial
management, and I think, you know, if you've got somebody
who can go in and talk to the practices, be receptive to their
problems, problem solve, then that seems to work" (GP7).
Clinical specialties were seen as differing in their research-
friendliness, with surgery posing particular difficulties.
"Surgery's quite an interesting area to do trials because it's very
difficult to persuade surgeons about uncertainty and exploring
uncertainty, so in the past we've tended to do cohort studies"
(HD4). General practice differed in continuing to offer
scope for payments to individual clinicians rather than to
employing trusts. Few differences were found by geo-
graphical location, between clinicians and non-clinicians
or between medical specialties. Clinicians who were no
longer research active tended to emphasise the same neg-
ative factors as others, albeit more strongly.
Discussion
The funding of clinical trials has become more transparent
in recent years, due largely to ethics committee require-
ments and clinical governance. Payments for clinical
involvement in both publicly and privately funded studies
must flow to NHS employing organisations rather than
individual clinicians. The requirement that full details of
trial funding be made available to ethics committees not
only increased transparency but made departures from
recommended practice more difficult.
The findings on the factors motivating clinicians to partic-
ipate in clinical trials provide UK evidence consistent with
the few studies in other countries [9]. Interest in the
research question, intellectual curiosity and potential ben-
efits to patients were the most important factors. Payment
for involvement was seen as less important and likely to
have negative effects.
The boundary between paying and not paying for partici-
pation in clinical research is blurred by the acceptance by
interviewees of the principle (and increasingly the prac-
tice) that the costs of research should be reimbursed.
Expenses however are difficult to define unambiguously
as they can be limited to expenses incurred or extended to
include payment for the opportunity cost of time, such as
time taken 'off-work' (either within or without employed
hours) or leisure. While economists would argue that theTrials 2009, 10:15 http://www.trialsjournal.com/content/10/1/15
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right price would be that which led to target recruitment
within time, several interviewees suggested a test: "would
they be comfortable making public how much they
received per patient recruited?" If the answer was no, then
the payment was too high.
In the future, differences in funding and costs may
become clearer when the NHS hosts both commercial and
non-commercial trials within a single structure. All future
trials in the NHS will have to be run through clinical
research networks, which already exist for key diseases
(cancer, mental health, diabetes, stroke, elderly, children,
neurodegenerative diseases) with a comprehensive net-
work to include all other diseases. "A key characteristic of
the NHS networks will be to support and conduct ran-
domised controlled trials and well designed studies for
commercial and non-commercial sponsors. This will
include pivotal licensing studies undertaken for industry
on a full cost recovery basis." [24].
While we believe the findings of this study are valid, lim-
itations are inevitable. One concerns restricting the inter-
view sample to researchers in receipt of NHS HTA
programme funding. Against this, most of these had
received funding from other bodies, particularly the Med-
ical Research Council and some had been involved in tri-
als for the pharmaceutical industry. More important
perhaps, all agreed to be interviewed free of charge, which
may have biased the sample towards those who do
research for reasons other than money. It also proved dif-
ficult to achieve the sample of researchers who were no
longer active.
Conclusion
Payment of clinicians beyond expenses is perceived to be
a less important motivating factor than researching
important, salient questions, and facilitating research by
reducing bureaucracy and delay.
The exploratory research reported here indicated topics
which might usefully be further researched including col-
lecting improved data on the use of different motivating
factors (including payments) for both clinician and
patient involvement in clinical trials, monitoring the
effects of the EU directive on Good Clinical Practice on the
progress of clinical trials, researching the role of collabo-
rators in clinical trials, and finally experimenting with the
most promising motivating factors by randomising them
within the context of multicentre clinical trials.
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